Company intelligence / Profile preview

Hitachi

Ownership: Public · 6501
Employees: ~268655
Development stage: Commercial

Overview

Hitachi provides advanced digital and automation solutions to support the manufacturing, quality assurance, and traceability of cell and gene therapies. Its platforms are used in clinical studies (e.g., iPS cell-derived dopamine neural precursors in Parkinson’s disease trials) and commercial settings to ensure safety, compliance, and efficiency across the regenerative medicine value chain.

Modalities: DeviceCell therapy
Industry: Biomedical IT and Biomedical Data Platforms

Partnerships

Mass General Brigham/Brigham & Women’s Hospital

Financials

Market cap: $128B
Total revenue: $66.9B
Enterprise value: $124.9B

Beyond the preview

Go deeper on Hitachi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hitachi.